Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-05-04

FDA Approved: MIRALAX — Supplemental Application (Bayer HealthCare LLC.)

View source ↗

Summary

The FDA approved a supplemental application for MIRALAX (polyethylene glycol 3350) from Bayer HealthCare LLC, updating its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MIRALAX (POLYETHYLENE GLYCOL 3350)

Snippet

SUPPL AP for MIRALAX (POLYETHYLENE GLYCOL 3350)